Veritas In Silico Inc
130A
Company Profile
Business description
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
Contact
1-11-1, Nishigotanda
Shinagawa-ku
Tokyo141-0031
JPNT: +81 -364217537
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 29.30 | -0.32% |
| CAC 40 | 8,235.98 | 23.62 | -0.29% |
| DAX 40 | 23,742.44 | 61.51 | -0.26% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,582.96 | 17.57 | -0.17% |
| HKSE | 25,757.87 | 97.02 | 0.38% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,805.60 | 1,302.83 | 2.31% |
| NZX 50 Index | 13,017.26 | 2.92 | -0.02% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,983.30 | 30.70 | -0.34% |
| SSE Composite Index | 4,005.20 | 16.64 | 0.42% |